Share Email Print

Proceedings Paper

Radiosensitization of hematoporphyrin derivative: clinical trial on 69 patients
Author(s): Shao-Yong Huang; Tian-Hu Yu
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Sixty-nine patients with various malignant tumors were treated with different regimens of radiotherapy or chemotherapy combined with HpD. The immediate response showed that the over-all response rate was 94.2% and complete response rate was 60.9%. The present study suggests that HpD be used as a radiosensitizer with mild side effects but no drug resistance on repeated administrations. Special effects of HpD on radio-resistant tumors, such as malignant melanoma, were observed. It may render radiation effective in advanced or recurrent lesions. Mechanism of radiosensitization of HpD is discussed. Tentative ideas for further investigations are put forward.

Paper Details

Date Published: 5 March 1993
PDF: 5 pages
Proc. SPIE 1616, International Conference on Photodynamic Therapy and Laser Medicine, (5 March 1993); doi: 10.1117/12.137012
Show Author Affiliations
Shao-Yong Huang, Tianjin Cancer Hospital and Institute (China)
Tian-Hu Yu, Tianjin Second Medical College (China)

Published in SPIE Proceedings Vol. 1616:
International Conference on Photodynamic Therapy and Laser Medicine
Junheng Li M.D., Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?